Embecta Corp. is a pure-play diabetes care company. Embecta is based in FRANKLIN LAKES, N.J.
| Revenue (Most Recent Fiscal Year) | $1.08B |
| Net Income (Most Recent Fiscal Year) | $95.40M |
| PE Ratio (Current Year Earnings Estimate) | 2.06 |
| PE Ratio (Trailing 12 Months) | 1.28 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.19 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 0.83 |
| Pre-Tax Margin (Trailing 12 Months) | 16.27% |
| Net Margin (Trailing 12 Months) | 10.73% |
| Return on Equity (Trailing 12 Months) | -23.96% |
| Return on Assets (Trailing 12 Months) | 14.12% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.46 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.68 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 2.14 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-10.55 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.27 |
| Earnings per Share (Most Recent Fiscal Year) | $2.95 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.90 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Common Shares Outstanding | 59.33M |
| Free Float | 58.56M |
| Market Capitalization | $196.97M |
| Average Volume (Last 20 Days) | 3.70M |
| Beta (Past 60 Months) | 1.09 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 93.83% |
| Annual Dividend (Based on Last Quarter) | $0.60 |
| Dividend Yield (Based on Last Quarter) | 18.07% |